Skip to main content
Erschienen in: Diabetologia 2/2019

15.11.2018 | Article

Therapeutic regulation of VE-cadherin with a novel oligonucleotide drug for diabetic eye complications using retinopathy mouse models

verfasst von: Ka Ka Ting, Yang Zhao, Weiyong Shen, Paul Coleman, Michelle Yam, Tailoi Chan-Ling, Jia Li, Thorleif Moller, Mark Gillies, Mathew A. Vadas, Jennifer R. Gamble

Erschienen in: Diabetologia | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

A major feature of diabetic retinopathy is breakdown of the blood–retinal barrier, resulting in macular oedema. We have developed a novel oligonucleotide-based drug, CD5-2, that specifically increases expression of the key junctional protein involved in barrier integrity in endothelial cells, vascular-endothelial-specific cadherin (VE-cadherin). CD5-2 prevents the mRNA silencing by the pro-angiogenic microRNA, miR-27a. CD5-2 was evaluated in animal models of ocular neovascularisation and vascular leak to determine its potential efficacy for diabetic retinopathy.

Methods

CD5-2 was tested in three mouse models of retinal dysfunction: conditional Müller cell depletion, streptozotocin-induced diabetes and oxygen-induced retinopathy. Vascular permeability in the Müller cell-knockout model was assessed by fluorescein angiography. The Evans Blue leakage method was used to determine vascular permeability in streptozotocin- and oxygen-induced retinopathy models. The effects of CD5-2 on retinal neovascularisation, inter-endothelial junctions and pericyte coverage in streptozotocin- and oxygen-induced retinopathy models were determined by staining for isolectin-B4, VE-cadherin and neural/glial antigen 2 (NG2). Blockmir CD5-2 localisation in diseased retina was determined using fluorescent in situ hybridisation. The effects of CD5-2 on VE-cadherin expression and in diabetic retinopathy-associated pathways, such as the transforming growth factor beta (TGF-β) and wingless/integrated (WNT) pathway, were confirmed using western blot of lysates from HUVECs, a mouse brain endothelial cell line and a VE-cadherin null mouse endothelial cell line.

Results

CD5-2 penetrated the vasculature of the eye in the oxygen-induced retinopathy model. Treatment of diseased mice with CD5-2 resulted in reduced vascular leak in all three animal models, enhanced expression of VE-cadherin in the microvessels of the eye and improved pericyte coverage of the retinal vasculature in streptozotocin-induced diabetic models and oxygen-induced retinopathy models. Further, CD5-2 reduced the activation of retinal microglial cells in the streptozotocin-induced diabetic model. The positive effects of CD5-2 seen in vivo were further confirmed in vitro by increased protein expression of VE-cadherin, SMAD2/3 activity, and platelet-derived growth factor B (PDGF-B).

Conclusions/interpretation

CD5-2 has therapeutic potential for individuals with vascular-leak-associated retinal diseases based on its ease of delivery and its ability to reverse vascular dysfunction and inflammatory aspects in three animal models of retinopathy.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Cunha-Vaz J, Bernardes R, Lobo C (2011) Blood-retinal barrier. Eur J Ophthalmol 21(Suppl 6):S3–S9CrossRefPubMed Cunha-Vaz J, Bernardes R, Lobo C (2011) Blood-retinal barrier. Eur J Ophthalmol 21(Suppl 6):S3–S9CrossRefPubMed
7.
Zurück zum Zitat Semeraro F, Cancarini A, dell’Omo R, Rezzola S, Romano MR, Costagliola C (2015) Diabetic retinopathy: vascular and inflammatory disease. J Diabetes Res 2015:582060CrossRefPubMedPubMedCentral Semeraro F, Cancarini A, dell’Omo R, Rezzola S, Romano MR, Costagliola C (2015) Diabetic retinopathy: vascular and inflammatory disease. J Diabetes Res 2015:582060CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Yan Y, Chang Q, Li Q et al (2015) Identification of plasma vascular endothelia-cadherin as a biomarker for coronary artery disease in type 2 diabetes mellitus patients. Int J Clin Exp Med 8(10):19466–19470PubMedPubMedCentral Yan Y, Chang Q, Li Q et al (2015) Identification of plasma vascular endothelia-cadherin as a biomarker for coronary artery disease in type 2 diabetes mellitus patients. Int J Clin Exp Med 8(10):19466–19470PubMedPubMedCentral
18.
Zurück zum Zitat He J, Wang H, Liu Y, Li W, Kim D, Huang H (2015) Blockade of vascular endothelial growth factor receptor 1 prevents inflammation and vascular leakage in diabetic retinopathy. J Ophthalmol 2015:605946CrossRefPubMedPubMedCentral He J, Wang H, Liu Y, Li W, Kim D, Huang H (2015) Blockade of vascular endothelial growth factor receptor 1 prevents inflammation and vascular leakage in diabetic retinopathy. J Ophthalmol 2015:605946CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Nielsen LB, Wang C, Sorensen K et al (2012) Circulating levels of microRNA from children with newly diagnosed type 1 diabetes and healthy controls: evidence that miR-25 associates to residual beta-cell function and glycaemic control during disease progression. Exp Diabetes Res 2012:896362PubMedPubMedCentral Nielsen LB, Wang C, Sorensen K et al (2012) Circulating levels of microRNA from children with newly diagnosed type 1 diabetes and healthy controls: evidence that miR-25 associates to residual beta-cell function and glycaemic control during disease progression. Exp Diabetes Res 2012:896362PubMedPubMedCentral
25.
Zurück zum Zitat Smith LE, Wesolowski E, McLellan A et al (1994) Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 35(1):101–111PubMed Smith LE, Wesolowski E, McLellan A et al (1994) Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 35(1):101–111PubMed
37.
Zurück zum Zitat McGuire PG, Rangasamy S, Maestas J, Das A (2011) Pericyte-derived sphingosine 1-phosphate induces the expression of adhesion proteins and modulates the retinal endothelial cell barrier. Arterioscler Thromb Vasc Biol 31:e107–e115CrossRefPubMedPubMedCentral McGuire PG, Rangasamy S, Maestas J, Das A (2011) Pericyte-derived sphingosine 1-phosphate induces the expression of adhesion proteins and modulates the retinal endothelial cell barrier. Arterioscler Thromb Vasc Biol 31:e107–e115CrossRefPubMedPubMedCentral
45.
Zurück zum Zitat da Fonseca AC, Matias D, Garcia C et al (2014) The impact of microglial activation on blood-brain barrier in brain diseases. Front Cell Neurosci 8:362CrossRefPubMedPubMedCentral da Fonseca AC, Matias D, Garcia C et al (2014) The impact of microglial activation on blood-brain barrier in brain diseases. Front Cell Neurosci 8:362CrossRefPubMedPubMedCentral
Metadaten
Titel
Therapeutic regulation of VE-cadherin with a novel oligonucleotide drug for diabetic eye complications using retinopathy mouse models
verfasst von
Ka Ka Ting
Yang Zhao
Weiyong Shen
Paul Coleman
Michelle Yam
Tailoi Chan-Ling
Jia Li
Thorleif Moller
Mark Gillies
Mathew A. Vadas
Jennifer R. Gamble
Publikationsdatum
15.11.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
Diabetologia / Ausgabe 2/2019
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-018-4770-4

Weitere Artikel der Ausgabe 2/2019

Diabetologia 2/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.